 PURPOSE
To authorize and describe procedures for EMS personnel to distribute “Leave Behind Naloxone” kits to individuals who 
are at risk for experiencing an opioid overdose. “Leave Behind Naloxone” kits may also be distributed to individuals who 
may come in contact with individuals who are at risk for experiencing an opioid overdose.

AUTHORITY
California Health and Safety Code - Division 2.5: Emergency Medical Services [1797. - 1799.207.]
California Civil Code Section 1714.22

BACKGROUND
The Naloxone Distribution Project (NDP) is a federally funded “Leave Behind Naloxone” initiative administered by the 
Department of Health Care Services (DHCS) in California to combat opioid overdose-related deaths through the free 
distribution of Naloxone to qualifying entities for the purpose of distribution to persons at risk for opioid overdose and 
those in a position to assist those persons at risk. EMS agencies in California are qualified entities to participate in this 
program. The NDP program is currently active in Riverside County through other community-based organizations; this 
program will now be extended to include distribution by EMS personnel who come in contact with high-risk individuals 
through the EMS system.

RESOURCES
https://www.dhcs.ca.gov/individuals/Pages/Naloxone_Distribution_Project.aspx
https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/SACB/Pages/Naloxone-Standing-Order.aspx

REQUIREMENTS
• All patients treated for an opioid overdose shall be assessed and managed in accordance with REMSA Policy #4601 
(Overdose / Adverse Reaction).
• All patients treated for an opioid overdose who refuse transport shall be managed in accordance with REMSA Policy 
#4107 (Refusal of Treatment and/or Transport).
• This policy applies only to “Leave Behind Naloxone” kits intended for laypersons’ use.
• This policy does not refer to any Naloxone in the responding units’ required medication inventory, as outlined in 
REMSA Policy #3303 (Drug and Equipment List).
• EMS personnel shall document distribution of “Leave Behind Naloxone” kits in compliance with local and state 
reporting as required.